Advanced or Metastatic Breast Cancer clinical trials

BR111 for advanced cancers

This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.

NanoKnife treatment for advanced pancreatic cancer

This trial studies a procedure called NanoKnife IRE for pancreatic cancer that cannot be removed surgically after standard chemotherapy or radiation. It uses electric pulses to destroy tumor cells and may be an option for patients who have completed other treatments.

ZGGS18 plus ZG005 for advanced solid tumors

This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.

Cold therapy, immunotherapy, and chemo before and after lung cancer surgery

This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.

Gum graft study for lower jaw recessions

This study compares two gum grafting methods (one using a special collagen material plus soft tissue, the other using soft tissue alone) to treat multiple gum recessions on the lower jaw. It may help find a better way to cover exposed roots and improve gum health.

Study of glumetinib plus nab-docetaxel for advanced stomach cancer

This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.

Study of WJB001 combined therapy for advanced solid tumors

This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.

Personalized mRNA vaccine for advanced bile duct cancer

This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.

Short-course radiation plus chemo and immunotherapy for rectal cancer

This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.

Study of JAB-23E73 for KRAS-Altered Advanced Tumors

This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.

Study of TGW101 for advanced solid tumors

This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.

Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients

This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.

JAB-23E73 for Advanced Solid Tumors with KRAS Changes

This trial tests a new drug called JAB-23E73 for people with advanced solid tumors that have a specific change in the KRAS gene. It may be an option if previous treatments have stopped working or are not suitable.

Porphysome nanoparticles for imaging advanced gynecological cancers

This early-phase trial tests a new imaging agent called Porphysome nanoparticles to see if it can help doctors see gynecological cancers more clearly on scans. It's for women with advanced cancer that cannot be cured, and who are already receiving standard treatments like chemotherapy.

PLD vs. observation for advanced soft tissue sarcoma

This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

Study of new drug combinations for advanced liver cancer

This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.

New drug combo for advanced HER2-positive endometrial cancer

This trial tests two new drug combinations (trastuzumab deruxtecan plus either rilvegostomig or pembrolizumab) as a first treatment for advanced HER2-positive, pMMR endometrial cancer. The goal is to see if these combinations shrink tumors or delay cancer growth.

Testing a new drug for advanced solid tumors

This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.

Testing FP008 in advanced solid tumors

This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.

Study of GSK5458514 alone or with other drugs for prostate cancer

This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.

Comparing two drug combinations for advanced colorectal cancer

This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.

Study of H1710 for advanced solid tumors

This trial tests a new drug called H1710 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if H1710 is safe and effective.

Phase I Study of HBT-708 for Patients With Advanced Solid Tumors